SCHEMBL1414224

SCHEMBL1414224

O=c1cc(/C=C/c2ccccc2)c2ccccc2o1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.71
SMN1; SMN2 Q16637 3/20 0.71
LMNA P02545 1/20 0.71
HPGD P15428 3/20 0.58
KDM4E B2RXH2 1/20 0.58
NPC1 O15118 1/20 0.58
MAPT P10636 1/20 0.58
RAB9A P51151 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
MAOB P27338 1/20 0.54
NQO1 P15559 2/20 0.51
CA12 O43570 2/20 0.50
CA1 P00915 2/20 0.50
CA9 Q16790 2/20 0.50
CDC25A P30304 2/20 0.48
CDC25C P30307 2/20 0.48
GRM4 Q14833 1/20 0.47
MCHR1 Q99705 1/20 0.44
MT-CO2 P00403 1/20 0.44
BCHE P06276 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1414225 1.00 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2LMNAHPGDKDM4E
SCHEMBL25361394 0.84 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2LMNAHPGDKDM4E
SCHEMBL21457082 0.82 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2LMNAHPGDKDM4E
SCHEMBL21457085 0.82 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2LMNAHPGDKDM4E
SCHEMBL28695610 0.81 NQO1 (0.53) ALDH1A1SMN1; SMN2LMNAHPGDKDM4E
SCHEMBL17384233 0.81 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2LMNAHPGDKDM4E
SCHEMBL17384225 0.80 CDC25A (0.69) ALDH1A1SMN1; SMN2LMNAHPGDKDM4E
SCHEMBL1395382 0.79 NQO1 (0.58) ALDH1A1SMN1; SMN2LMNAHPGDKDM4E
SCHEMBL15953090 0.77 NQO1 (0.61) ALDH1A1SMN1; SMN2LMNAHPGDKDM4E
SCHEMBL3210892 0.77 NQO1 (0.56) ALDH1A1SMN1; SMN2LMNAHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2295053-B1 Novel 2H-chromen-2-one-3-carboxamides for medical uses INST MATERIA MEDICA CAMS (CN) 2016-10-19 EP disclosed
US-8338401-B2 Coumarin-amide derivatives and its preparation, said drug composition and its use INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2012-12-25 US disclosed
EP-2295053-A1 Novel 2H-chromen-2-one-3-carboxamides for medical uses THE INSTITUTE OF MATERIA MEDICA OF CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2011-03-16 EP disclosed
US-20060148834-A1 Novel coumarin-amide derivatives and its preparation, said drug composition and its use INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2006-07-06 US disclosed
EP-1570846-A1 THE NOVEL COUMARIN-AMIDE DERIVATIVES AND ITS PREPARATION, SAID DRUG COMPOSITION AND ITS USE THE INSTITUTE OF MATERIA MEDICA OF CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2005-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148834-A1 Novel coumarin-amide derivatives and its preparation, said drug composition and its use INSR, GLS, INSRR ALDH1A1 1795/4885SMN1; SMN2 4803/4885LMNA 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.